Physician profile
Sandipkumar Patel
NPI 1053973859
$4,138.47
in general payments reported to CMS, 2019-2025
20 companies · $1,302 in 2025
The $1,302 reported for 2025 was more than what 94% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.17 · 2020: $173 · 2021: $232 · 2022: $928 · 2023: $484 · 2024: $945 · 2025: $1,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,606 · Entertainment: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,605.84 |
| Entertainment | $125.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $617.29 | 2020-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Horizon Therapeutics Plc | $367.61 | 2023 | Tepezza |
| Dompe US, INC. | $364.01 | 2022-2025 | Oxervate |
| Amgen INC. | $353.96 | 2024-2025 | Tepezza |
| Johnson & Johnson Vision Care, INC. | $260.13 | 2024 | |
| Lkc Technologies, INC. | $246.24 | 2023-2025 | |
| Bausch & Lomb Americas INC. | $242.55 | 2024-2025 | Miebo, Xiidra |
| Glaukos Corporation | $242.28 | 2022 | |
| Genzyme Corporation | $205.57 | 2019-2022 | |
| Alcon Vision LLC | $168.43 | 2022-2025 | Dailies Total1, Precision 1 |
| Optos, INC. | $166.29 | 2020-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Ocular Therapeutix, INC. | $150.00 | 2025 | Dextenza |
| Abbvie INC. | $124.59 | 2022 | |
| Kala Pharmaceuticals, INC. | $118.39 | 2021 | |
| Eyevance Pharmaceuticals LLC | $117.15 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $113.95 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $113.06 | 2024-2025 | Xdemvy |
| Harrow Eye, LLC | $108.75 | 2025 | Vevye |
| The Walman Optical Company | $40.98 | 2025 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandipkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.